Table 2 Characteristics of patients of international validation cohort by participating center and the initial Spanish cohort [2]

Subjects, (n)

108

83

101

103

187

69

819

Age in years

44.4 ± 16.8

45.1 ± 15.7

52.5 ± 17.7

47.1 ± 15.6

47.4 ± 14.5

54.5 ± 13.8

0.0001

58.7 ± 17.6

Male (%)

33.3%

25.3%

18.8%

42.7%

34.2%

43.5%

0.002

43.5%

 Post-infective

55.6%

47.0%

60.4%

16.5%

24.6%

62.7%

0.00000

31.3%

 Idiopathic

34.3%

25.3%

26.7%

44.7%

34.2%

5.9%

1

37.9%

Dyspnea mMRC score

1.16 ± 0.8

1.32 ± 1.3

1.90 ± 1.0

1.71 ± 0.9

1.53 ± 0.9

1.47 ± 1.0

0.00001

1.53 ± 1.1

Mucopurulent or purulent sputum appearance (%)

61.1%

75.9%

71.1%

52.4%

44.2%

34.8%

0.0001

35.4%

Respiratory insufficiency (%)

14.8%

13.3%

15.8%

29.1%

16.1%

10.1%

0.013

10.1%

Lobes affected

3.0 ± 1.3

2.8 ± 1.0

3.1 ± 1.2

3.7 ± 1.5

3.9 ± 1.6

2.6 ± 1.2

0.0001

2.52 ± 1.2

FEV1 % of predicted

62.2 ± 21.7

57.5 ± 21.4

58.4 ± 23.8

49.1 ± 21.5

49.6 ± 19.9

54.7 ± 22.0

0.000001

68.9 ± 25.9

Chronic colonization by PA (%)

58.3%

36.1%

23.8%

52.4%

40.6%

17.4%

0.0001

31.8%

Exacerbations in previous year**

1.04 (0.83)

2.6 (1.01)

1.25 (1.3)

0.81 (1.2)

0.7 (1.7)

0.9 (0.94)

0.001

2.52 (2.2)

Hospitalizations in previous year

0.47 ± 0.6

0.61 ± 0.8

0.28 ± 0.6

0.26 ± 0.6

0.28 ± 0.9

0.49 ± 0.6

0.005

0.7 ± 1.2

Exacerbation rate (per year)**

1.05 (0.6)

0.8 (0.6)

1.2 (0.92)

1.24 (1)

0.75 (0.97)

0.8 (0.58)

0.01

--

Hospitalization rate (per year)

0.4 (0.41)

0.3 (0.5)

0.42 (0.64)

0.37 (0.78)

0.12 (0.37)

0.18 (0.38)

0.009

--

Death (%)

21 (13.6%)

12 (14.5%)

11 (10.1%)

14 (19.4%)

30 (16.0%)

7 (10.9%)

0.46

18.8%

AUC-ROC (95CI%)

0.78 (0.67–0.89)

0.93 (0.86–0.99)

0.86 (0.76–0.95)

0.84 (0.75–0.92)

0.80 (0.70–0.87)

0.80 (0.73–0.96)

0.017⁺

0.87 (0.82–0.91)